Roundup Not Carcinogenic, Formula Won't Change After Settlement: Bayer CEO

The transcript discusses the resolution of glyphosate litigation, financial settlements, and the formation of a science panel to assess product safety. It highlights the acquisition of Monsanto by Bayer, emphasizing the benefits for innovation and agriculture. The company's strategy focuses on health and nutrition, with a strong outlook for future growth. Leadership and management decisions are also addressed, with a vote of confidence from the supervisory board.

What are the expected benefits of the merger with Monsanto for farmers?

What is the company's strategy moving forward in the areas of health and nutrition?

What challenges does the company face in the current market conditions?

What insights can be drawn from the company's recent AGM regarding management confidence?